
India's Dr Reddy's posts worst week in 3 years as semaglutide setback stokes growth fears
Dr Reddy’s Laboratories logged its steepest weekly loss in three years on Friday, after a disruption in generic semaglutide supply raised concerns it could lose its edge in the highly competitive diabetes market.

































.jpg)



























_20260601083729055_07be41.webp)





_20260513052023717_7e8bb5.jpeg)


















